mAb-话题@MedSci

#mAb#

1302篇内容 | 2842人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912844, encodeId=edb31912844d5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=99, createdTime=2022-07-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912868, encodeId=06bc1912868a7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, objectType=article, longId=729496, objectId=5ebee29496b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebee29496b6, replyNumber=0, likeNumber=67, createdTime=2022-09-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebee29496b6, moduleTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ebee29496b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912831, encodeId=767c19128315d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Arthritis Rheumatol：Brodalumab可有效治疗头皮和指甲银屑病的病损, objectType=article, longId=301790, objectId=90ed301e90ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90ed301e90ac, replyNumber=0, likeNumber=70, createdTime=2022-09-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90ed301e90ac, moduleTitle=Arthritis Rheumatol：Brodalumab可有效治疗头皮和指甲银屑病的病损, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90ed301e90ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912892, encodeId=b0d31912892a1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , objectType=article, longId=736658, objectId=f14be366588f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f14be366588f, replyNumber=0, likeNumber=70, createdTime=2023-05-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f14be366588f, moduleTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f14be366588f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912847, encodeId=6e12191284e43, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, objectType=article, longId=725405, objectId=f586e25405ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f586e25405ed, replyNumber=0, likeNumber=82, createdTime=2022-07-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f586e25405ed, moduleTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f586e25405ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912862, encodeId=2f761912862cd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, objectType=article, longId=728247, objectId=5740e2824790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5740e2824790, replyNumber=0, likeNumber=100, createdTime=2022-09-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5740e2824790, moduleTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5740e2824790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912791, encodeId=a4891912e9150, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：采用Cemiplimab治疗复发性宫颈癌, objectType=article, longId=295537, objectId=c58b29553e6f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58b29553e6f, replyNumber=0, likeNumber=66, createdTime=2022-11-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58b29553e6f, moduleTitle=NEJM：采用Cemiplimab治疗复发性宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c58b29553e6f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912781, encodeId=7e9f1912e817b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：纳武单抗+Lirilumab辅助治疗复发性头颈部鳞状细胞癌, objectType=article, longId=295065, objectId=466a295065dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=466a295065dc, replyNumber=0, likeNumber=83, createdTime=2022-06-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=466a295065dc, moduleTitle=Clin Cancer Res：纳武单抗+Lirilumab辅助治疗复发性头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=466a295065dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912774, encodeId=0e741912e740f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=75, createdTime=2022-04-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912765, encodeId=c7811912e6502, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, objectType=article, longId=293621, objectId=07a32936217f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07a32936217f, replyNumber=0, likeNumber=69, createdTime=2022-11-05, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07a32936217f, moduleTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07a32936217f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912747, encodeId=7f0e1912e477d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair, objectType=article, longId=292585, objectId=104d2925856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=104d2925856a, replyNumber=0, likeNumber=74, createdTime=2022-11-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=104d2925856a, moduleTitle=诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=104d2925856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912852, encodeId=1d21191285290, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌, objectType=article, longId=726278, objectId=022de262782e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022de262782e, replyNumber=0, likeNumber=88, createdTime=2022-06-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022de262782e, moduleTitle=Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022de262782e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912816, encodeId=7ee6191281662, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JACIP：Dupilumab单抗显示对特应性皮炎、哮喘、鼻窦炎并鼻息肉的快速反应, objectType=article, longId=300608, objectId=2a3a3006089d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a3a3006089d, replyNumber=0, likeNumber=83, createdTime=2022-06-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a3a3006089d, moduleTitle=JACIP：Dupilumab单抗显示对特应性皮炎、哮喘、鼻窦炎并鼻息肉的快速反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a3a3006089d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912730, encodeId=df741912e303b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响, objectType=article, longId=221429, objectId=2def221429fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2def221429fb, replyNumber=0, likeNumber=71, createdTime=2022-05-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2def221429fb, moduleTitle=JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2def221429fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912760, encodeId=34051912e60bb, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=86, createdTime=2022-07-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912891, encodeId=8e991912891e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, objectType=article, longId=736966, objectId=ac21e36966ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac21e36966ab, replyNumber=0, likeNumber=83, createdTime=2023-05-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac21e36966ab, moduleTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac21e36966ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912879, encodeId=035419128e9fa, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？, objectType=article, longId=732994, objectId=5689e3299402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5689e3299402, replyNumber=0, likeNumber=69, createdTime=2022-12-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5689e3299402, moduleTitle=Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5689e3299402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912769, encodeId=883e1912e6993, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=55, createdTime=2022-10-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912887, encodeId=18e5191288e26, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, objectType=article, longId=735447, objectId=b7ffe3544777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7ffe3544777, replyNumber=0, likeNumber=84, createdTime=2022-09-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7ffe3544777, moduleTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7ffe3544777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912790, encodeId=704c1912e9056, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab, objectType=article, longId=295530, objectId=2e9829553018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e9829553018, replyNumber=0, likeNumber=87, createdTime=2022-09-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e9829553018, moduleTitle=FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e9829553018)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌

2022-07-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌

2022-09-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Arthritis Rheumatol：Brodalumab可有效治疗头皮和指甲银屑病的病损

2022-09-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性

2023-05-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine

2022-07-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌

2022-09-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：采用Cemiplimab治疗复发性宫颈癌

2022-11-25

仁者大医 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：纳武单抗+Lirilumab辅助治疗复发性头颈部鳞状细胞癌

2022-06-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-04-02

柳叶一刀 (审核中...)

前往app查看评论内容

#mAb#

Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素

2022-11-05

snf701207 (审核中...)

前往app查看评论内容

#mAb#

诺华的ligelizumab在自发性荨麻疹研究中未能击败Xolair

2022-11-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌

2022-06-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JACIP：Dupilumab单抗显示对特应性皮炎、哮喘、鼻窦炎并鼻息肉的快速反应

2022-06-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响

2022-05-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-07-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较

2023-05-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？

2022-12-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-10-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估

2022-09-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab

2022-09-27

科室
- - 订阅+
  - 更多科室
工具
服务